| Dr Jude Aaron Fink, MD | |
|
415 6th St, Lewiston, ID 83501-2431 | |
| (512) 730-3056 | |
| (888) 730-1925 |
| Full Name | Dr Jude Aaron Fink |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 14 Years |
| Location | 415 6th St, Lewiston, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720308661 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | M12156 (Idaho) | Secondary |
| 207R00000X | Internal Medicine | M-12156 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Idaho Falls Community Hospital, Llc | Idaho falls, ID | Hospital |
| Mountain View Hospital | Idaho falls, ID | Hospital |
| Teton Valley Hospital | Driggs, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Snake River Hospitalists Llc | 7113359969 | 8 |
News Archive
Plextronics, Inc. announced today that it has completed a $14 million Series B-1 financing round. The round was led by Solvay North American Investments, LLC, a member of the Solvay Group, which is an international chemical and pharmaceutical group headquartered in Brussels, Belgium. Marking Solvay's second investment in three years, this $12 million investment makes Solvay the largest minority shareholder in Plextronics.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Heart attacks and strokes -; the leading causes of death in human beings -; are fundamentally blood clots of the heart and brain. Better understanding how the blood-clotting process works and how to accelerate or slow down clotting, depending on the medical need, could save lives.
Current strategies for treating patients with several chronic diseases are putting an unnecessary financial burden on countries' health systems and individuals, a global study led by the National University of Singapore and the University of Melbourne has found.
› Verified 2 days ago
| Entity Name | Kootenai Health, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235288655 PECOS PAC ID: 4789641598 Enrollment ID: O20041214000230 |
News Archive
Plextronics, Inc. announced today that it has completed a $14 million Series B-1 financing round. The round was led by Solvay North American Investments, LLC, a member of the Solvay Group, which is an international chemical and pharmaceutical group headquartered in Brussels, Belgium. Marking Solvay's second investment in three years, this $12 million investment makes Solvay the largest minority shareholder in Plextronics.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Heart attacks and strokes -; the leading causes of death in human beings -; are fundamentally blood clots of the heart and brain. Better understanding how the blood-clotting process works and how to accelerate or slow down clotting, depending on the medical need, could save lives.
Current strategies for treating patients with several chronic diseases are putting an unnecessary financial burden on countries' health systems and individuals, a global study led by the National University of Singapore and the University of Melbourne has found.
› Verified 2 days ago
| Entity Name | Utah Regional Hospitalists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740715507 PECOS PAC ID: 4789807165 Enrollment ID: O20170811001682 |
News Archive
Plextronics, Inc. announced today that it has completed a $14 million Series B-1 financing round. The round was led by Solvay North American Investments, LLC, a member of the Solvay Group, which is an international chemical and pharmaceutical group headquartered in Brussels, Belgium. Marking Solvay's second investment in three years, this $12 million investment makes Solvay the largest minority shareholder in Plextronics.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Heart attacks and strokes -; the leading causes of death in human beings -; are fundamentally blood clots of the heart and brain. Better understanding how the blood-clotting process works and how to accelerate or slow down clotting, depending on the medical need, could save lives.
Current strategies for treating patients with several chronic diseases are putting an unnecessary financial burden on countries' health systems and individuals, a global study led by the National University of Singapore and the University of Melbourne has found.
› Verified 2 days ago
| Entity Name | Hni Hospitalists Of Idaho Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528568326 PECOS PAC ID: 4284999889 Enrollment ID: O20180601000777 |
News Archive
Plextronics, Inc. announced today that it has completed a $14 million Series B-1 financing round. The round was led by Solvay North American Investments, LLC, a member of the Solvay Group, which is an international chemical and pharmaceutical group headquartered in Brussels, Belgium. Marking Solvay's second investment in three years, this $12 million investment makes Solvay the largest minority shareholder in Plextronics.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Heart attacks and strokes -; the leading causes of death in human beings -; are fundamentally blood clots of the heart and brain. Better understanding how the blood-clotting process works and how to accelerate or slow down clotting, depending on the medical need, could save lives.
Current strategies for treating patients with several chronic diseases are putting an unnecessary financial burden on countries' health systems and individuals, a global study led by the National University of Singapore and the University of Melbourne has found.
› Verified 2 days ago
| Entity Name | Snake River Hospitalists Llc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1790343580 PECOS PAC ID: 7113359969 Enrollment ID: O20191115001191 |
News Archive
Plextronics, Inc. announced today that it has completed a $14 million Series B-1 financing round. The round was led by Solvay North American Investments, LLC, a member of the Solvay Group, which is an international chemical and pharmaceutical group headquartered in Brussels, Belgium. Marking Solvay's second investment in three years, this $12 million investment makes Solvay the largest minority shareholder in Plextronics.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Heart attacks and strokes -; the leading causes of death in human beings -; are fundamentally blood clots of the heart and brain. Better understanding how the blood-clotting process works and how to accelerate or slow down clotting, depending on the medical need, could save lives.
Current strategies for treating patients with several chronic diseases are putting an unnecessary financial burden on countries' health systems and individuals, a global study led by the National University of Singapore and the University of Melbourne has found.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jude Aaron Fink, MD 7500 Rialto Blvd Ste 1-140, Austin, TX 78735-8534 Ph: (512) 730-3056 | Dr Jude Aaron Fink, MD 415 6th St, Lewiston, ID 83501-2431 Ph: (512) 730-3056 |
News Archive
Plextronics, Inc. announced today that it has completed a $14 million Series B-1 financing round. The round was led by Solvay North American Investments, LLC, a member of the Solvay Group, which is an international chemical and pharmaceutical group headquartered in Brussels, Belgium. Marking Solvay's second investment in three years, this $12 million investment makes Solvay the largest minority shareholder in Plextronics.
A team of researchers at the Salk Institute has found two therapeutic targets for the deadly type of lung cancer, non-small-cell lung carcinomas (NSCLCs), which accounts for 85 percent of all lung cancer cases. They believe that the breakthrough discovery could pave the way for the development of new treatments for a majority of lung cancer patients.
Heart attacks and strokes -; the leading causes of death in human beings -; are fundamentally blood clots of the heart and brain. Better understanding how the blood-clotting process works and how to accelerate or slow down clotting, depending on the medical need, could save lives.
Current strategies for treating patients with several chronic diseases are putting an unnecessary financial burden on countries' health systems and individuals, a global study led by the National University of Singapore and the University of Melbourne has found.
› Verified 2 days ago
Robert Alan Wales, MD, FACC Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 2315 8th St Grade, Lewiston, ID 83501 Phone: 509-455-8820 Fax: 509-227-7070 | |
David B Souvenir, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 415 6th St, Lewiston, ID 83501 Phone: 208-750-7204 Fax: 208-746-0134 | |
Jane A Fore, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 415 Sixth St, Lewiston, ID 83501 Phone: 208-750-7445 | |
Dr. Heather Fowler Cumbo, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 415 6th St, Lewiston, ID 83501 Phone: 208-750-7445 | |
Sushma Pant, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1250 Idaho Street, Lewiston, ID 83501 Phone: 208-743-7427 Fax: 208-743-7421 | |
Dr. Michael Rooney, M.D. Internal Medicine Medicare: Medicare Enrolled Practice Location: 415 6th St, Lewiston, ID 83501 Phone: 208-743-2511 Fax: 208-799-5528 | |
Dr. William Westel Rowe, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 415 6th St, Lewiston, ID 83501 Phone: 208-750-7507 |